APRE vs. ITRM, MRSN, OKUR, XLO, KLTO, ESLA, RNXT, SCYX, CLSD, and AKTX
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Iterum Therapeutics (ITRM), Mersana Therapeutics (MRSN), OnKure Therapeutics (OKUR), Xilio Therapeutics (XLO), Klotho Neurosciences (KLTO), Estrella Immunopharma (ESLA), RenovoRx (RNXT), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs. Its Competitors
Aprea Therapeutics (NASDAQ:APRE) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.
Aprea Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 881.01%. Iterum Therapeutics has a consensus target price of $9.00, indicating a potential upside of 1,217.14%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Aprea Therapeutics.
Iterum Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,645.01%. Iterum Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.
In the previous week, Iterum Therapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Iterum Therapeutics and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.
Iterum Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aprea Therapeutics and Iterum Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access